行情

FGEN

FGEN

纤维蛋白原
NASDAQ

实时行情|Nasdaq Last Sale

36.99
+2.01
+5.75%
盘后: 36.99 0 0.00% 16:41 11/15 EST
开盘
35.12
昨收
34.98
最高
37.59
最低
35.01
成交量
100.21万
成交额
--
52周最高
61.23
52周最低
32.33
市值
32.26亿
市盈率(TTM)
89.61
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

FGEN 新闻

  • FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm
  • Business Wire.2天前
  • Edited Transcript of FGEN earnings conference call or presentation 11-Nov-19 10:00pm GMT
  • Thomson Reuters StreetEvents.3天前
  • HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys, Firm Investigating Possible Securities Fraud
  • GlobeNewswire.3天前
  • Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors
  • Business Wire.3天前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

FGEN 简况

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
展开

Webull提供FibroGen Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。